Scinai Immunotherapeutics (SCNI) Competitors $2.16 -0.06 (-2.70%) Closing price 03:59 PM EasternExtended Trading$2.16 +0.00 (+0.19%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SCNI vs. IMNN, AEON, CLRB, MBRX, LIXT, CHRO, TRAW, XFOR, EVOK, and TSBXShould you be buying Scinai Immunotherapeutics stock or one of its competitors? The main competitors of Scinai Immunotherapeutics include Imunon (IMNN), AEON Biopharma (AEON), Cellectar Biosciences (CLRB), Moleculin Biotech (MBRX), Lixte Biotechnology (LIXT), Chromocell Therapeutics (CHRO), Traws Pharma (TRAW), X4 Pharmaceuticals (XFOR), Evoke Pharma (EVOK), and Turnstone Biologics (TSBX). These companies are all part of the "pharmaceutical products" industry. Scinai Immunotherapeutics vs. Its Competitors Imunon AEON Biopharma Cellectar Biosciences Moleculin Biotech Lixte Biotechnology Chromocell Therapeutics Traws Pharma X4 Pharmaceuticals Evoke Pharma Turnstone Biologics Imunon (NASDAQ:IMNN) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership. Do institutionals and insiders have more ownership in IMNN or SCNI? 4.5% of Imunon shares are held by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 6.0% of Imunon shares are held by company insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend IMNN or SCNI? Imunon currently has a consensus price target of $15.50, indicating a potential upside of 3,042.10%. Given Imunon's stronger consensus rating and higher probable upside, research analysts clearly believe Imunon is more favorable than Scinai Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Imunon 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75Scinai Immunotherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, IMNN or SCNI? Imunon has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500. Is IMNN or SCNI more profitable? Scinai Immunotherapeutics' return on equity of 0.00% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets ImunonN/A -427.98% -175.03% Scinai Immunotherapeutics N/A N/A -40.60% Does the media refer more to IMNN or SCNI? In the previous week, Imunon had 2 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 3 mentions for Imunon and 1 mentions for Scinai Immunotherapeutics. Scinai Immunotherapeutics' average media sentiment score of 1.89 beat Imunon's score of 1.19 indicating that Scinai Immunotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Imunon Positive Scinai Immunotherapeutics Very Positive Which has stronger earnings and valuation, IMNN or SCNI? Scinai Immunotherapeutics has higher revenue and earnings than Imunon. Imunon is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImunon$500K17.30-$18.62M-$1.36-0.36Scinai Immunotherapeutics$660K3.27$4.80M-$9.57-0.23 SummaryScinai Immunotherapeutics beats Imunon on 9 of the 16 factors compared between the two stocks. Get Scinai Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SCNI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCNI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCNI vs. The Competition Export to ExcelMetricScinai ImmunotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.22M$2.91B$5.52B$9.32BDividend YieldN/A2.46%4.25%4.05%P/E Ratio-0.2320.3628.1519.68Price / Sales3.27304.13438.32100.43Price / CashN/A42.3835.5357.53Price / Book0.427.768.235.67Net Income$4.80M-$55.11M$3.23B$257.51M7 Day Performance-7.69%0.95%-0.01%0.52%1 Month Performance-1.82%8.44%5.61%8.84%1 Year Performance-59.32%-2.38%26.52%14.18% Scinai Immunotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCNIScinai Immunotherapeutics1.2075 of 5 stars$2.16-2.7%N/A-62.3%$2.22M$660K-0.2320Positive NewsGap DownIMNNImunon2.4996 of 5 stars$0.53+2.3%$15.50+2,814.6%-62.0%$9.12M$500K-0.3930News CoverageGap DownAEONAEON Biopharma2.4042 of 5 stars$0.80-4.3%$360.00+44,956.3%-99.5%$9.03MN/A4.445CLRBCellectar Biosciences2.5378 of 5 stars$4.78-4.0%$375.00+7,745.2%-93.8%$9.02MN/A-0.2210Gap UpMBRXMoleculin Biotech2.9792 of 5 stars$0.63-0.2%$4.00+536.2%-85.1%$8.90MN/A0.0020Gap UpLIXTLixte Biotechnology0.2419 of 5 stars$3.71+12.4%N/A+53.9%$8.86MN/A-2.564Gap DownCHROChromocell TherapeuticsN/A$1.34+6.3%N/A-88.5%$8.69MN/A-1.084Gap UpHigh Trading VolumeTRAWTraws PharmaN/A$1.48-3.9%N/AN/A$8.57M$227K-0.0517News CoverageXFORX4 Pharmaceuticals4.7786 of 5 stars$1.47-0.7%$72.33+4,820.6%-93.1%$8.57M$31.36M0.6980Positive NewsHigh Trading VolumeEVOKEvoke Pharma0.8227 of 5 stars$5.13-10.6%N/A-27.5%$8.56M$11.59M-1.794Gap DownTSBXTurnstone Biologics3.4079 of 5 stars$0.36-0.6%$0.45+25.4%-85.8%$8.35M$19.31M-0.1382Positive News Related Companies and Tools Related Companies Imunon Alternatives AEON Biopharma Alternatives Cellectar Biosciences Alternatives Moleculin Biotech Alternatives Lixte Biotechnology Alternatives Chromocell Therapeutics Alternatives Traws Pharma Alternatives X4 Pharmaceuticals Alternatives Evoke Pharma Alternatives Turnstone Biologics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCNI) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scinai Immunotherapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Scinai Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SCNI Stock Alerts